Rudy Bret J, Lindsey Jane C, Flynn Patricia M, Bosch Ronald J, Wilson Craig M, Hughes Michael E, Douglas Steven D
Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
AIDS Res Hum Retroviruses. 2006 Mar;22(3):213-21. doi: 10.1089/aid.2006.22.213.
The responses to HAART in HIV-infected adolescents infected through risk behaviors are not well defined. PACTG 381 collected intensive immunologic and virologic data on youth naive to or with minimal exposure to antiretroviral therapy who began HAART. Subjects were evaluated according to their weeks 16-24 virologic response. Comparisons with a cohort of HIV-uninfected adolescents from the REACH cohort were performed. Cox proportional hazards models were used to identify baseline and week 24 predictors of virologic failure. Only 69 of 120 subjects (58%) achieved virologic suppression by weeks 16-24, whereas 55 of 69 (80%) demonstrated control to week 60. Higher CD4+ naive T cells (CD4+/62L+/RA+: hazard ratio [HR], 2.13; p = 0.018), higher CD8+ activated T cells (CD8+/CD38+/DR+: HR, 1.40, p = 0.028 per 100 cells/mm3) and higher CD8+ naive T cells (CD8+/62L+/RA+: HR, 1.72; p = 0.005) at weeks 16-24 in subjects with early viral success were predictive of subsequent failure. By week 60, total CD4+ T cells remained significantly lower than in uninfected controls. Adolescents beginning HAART achieve moderate rates of viral suppression by weeks 16-24. In those who do achieve early virologic control, suppression to week 60 is high although total CD4+ T cells remain significantly lower than in uninfected controls. Several T cell markers were predictive of subsequent virologic failure in subjects achieving short-term success. Further study is warranted to determine whether these predictors provide any benefit to clinical management.
通过危险行为感染艾滋病毒的青少年对高效抗逆转录病毒治疗(HAART)的反应尚不明确。艾滋病临床试验组(PACTG)381收集了开始接受HAART治疗的初治或极少接触抗逆转录病毒治疗的青少年的详细免疫和病毒学数据。根据第16 - 24周的病毒学反应对受试者进行评估。与来自REACH队列的未感染艾滋病毒的青少年队列进行了比较。采用Cox比例风险模型来确定病毒学失败的基线和第24周预测因素。120名受试者中只有69名(58%)在第16 - 24周实现了病毒学抑制,而69名中的55名(80%)在第60周时仍处于病毒学控制状态。早期病毒学成功的受试者在第第16 - 24周时,较高的初始CD4 + T细胞(CD4 + /62L + /RA +:风险比[HR],2.13;p = 0.018)、较高的活化CD8 + T细胞(CD8 + /CD38 + /DR +:HR,1.40,每100个细胞/mm3,p = 0.028)和较高的初始CD8 + T细胞(CD8 + /62L + /RA +:HR,1.72;p = 0.005)可预测随后的病毒学失败。到第60周时,总的CD4 + T细胞仍显著低于未感染的对照组。开始接受HAART治疗的青少年在第16 - 24周时实现病毒学抑制的比例适中。在那些确实实现早期病毒学控制的青少年中,到第60周时病毒学抑制率较高,尽管总的CD4 + T细胞仍显著低于未感染的对照组。几种T细胞标志物可预测短期成功的受试者随后的病毒学失败。有必要进行进一步研究以确定这些预测因素是否能为临床管理带来任何益处。